Demência com corpos de Lewy

Referências

Principais artigos

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.Texto completo  Resumo

Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13(5). pii: PCC.11r01190.Texto completo  Resumo

Galvin JE. Improving the clinical detection of lewy body dementia with the lewy body composite risk score. Alzheimers Dement (Amst). 2015 Sep 1;1(3):316-24.Texto completo  Resumo

Fischer C, Bozanovic R, Atkins JH, et al. Treatment of delusions in dementia with Lewy bodies: response to pharmacotherapy. Dement Geriatr Cogn Disord. 2007;23(5):307-11. Resumo

O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-68.Texto completo  Resumo

Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504.Texto completo  Resumo

Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):164-71.Texto completo  Resumo

Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. Resumo

Drach LM. Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia: common features and differences [in German]. Med Monatsschr Pharm. 2011 Feb;34(2):47-52. Resumo

Artigos de referência

1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.Texto completo  Resumo

2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition. (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

3. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996 Nov;47(5):1113-24. Resumo

4. Ferman TJ, Smith GE, Kantarci K, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013 Dec 3;81(23):2032-8. Resumo

5. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005 Nov;34(6):561-6.Texto completo  Resumo

6. Rampello L, Cerasa S, Alvano A, et al. Dementia with Lewy bodies: a review. Arch Gerontol Geriatr. 2004 Jul-Aug;39(1):1-14. Resumo

7. Bogaerts V, Engelborghs S, Kumar-Singh S, et al. A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain. 2007 Sep;130(Pt 9):2277-91.Texto completo  Resumo

8. Ohara K, Takauchi S, Kokai M, et al. Familial dementia with Lewy bodies (DLB). Clin Neuropathol. 1999 Sep-Oct;18(5):232-9. Resumo

9. Rosenberg CK, Cummings TJ, Saunders AM, et al. Dementia with Lewy bodies and Alzheimer's disease. Acta Neuropathol. 2001 Dec;102(6):621-6. Resumo

10. Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014 Dec 1;23(23):6139-46Texto completo  Resumo

11. Samuel W, Galasko D, Masliah E, et al. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol. 1996 Jan;55(1):44-52. Resumo

12. Weisman D, Cho M, Taylor C, et al. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology. 2007 Jul 24;69(4):356-9. Resumo

13. Yamada T, Kadekaru H, Matsumoto S, et al. Prevalence of dementia in the older Japanese-Brazilian population. Psychiatry Clin Neurosci. 2002 Feb;56(1):71-5. Resumo

14. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004 Jan 27;62(2):181-7. Resumo

15. Fahn S, Elton RL; UPDRS program members. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al, eds. Recent developments in Parkinson’s disease. Vol 2. Florham Park, NJ: Macmillan Healthcare; 1987:153-163.

16. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308-14. Resumo

17. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology. 2003 Jul 8;61(1):40-5. Resumo

18. Boeve BF, Silber MH, Parisi JE, et al. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):146-57.Texto completo  Resumo

19. Vendette M, Gagnon JF, Soucy JP, et al. Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder. Mov Disord. 2011 Aug 1;26(9):1717-24. Resumo

20. Lee DR, Taylor JP, Thomas AJ. Assessment of cognitive fluctuation in dementia: a systematic review of the literature. Int J Geriatr Psychiatry. 2012 Oct;27(10):989-98. Resumo

21. Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13(5). pii: PCC.11r01190.Texto completo  Resumo

22. Galvin JE. Improving the clinical detection of lewy body dementia with the lewy body composite risk score. Alzheimers Dement (Amst). 2015 Sep 1;1(3):316-24.Texto completo  Resumo

23. Puñal Riobóo J, Varela Lema L, Serena Puig A, et al. Effectiveness of 123I-ioflupane (DaTSCAN) in the diagnosis of Parkinsonian syndromes: a systematic review [in Spanish]. Rev Esp Med Nucl. 2007 Nov-Dec;26(6):375-84. Resumo

24. Quigley H, Colloby SJ, O'Brien JT. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry. 2011 Oct;26(10):991-9. Resumo

25. Bonanni L, Franciotti R, Nobili F, et al. EEG markers of dementia with Lewy bodies: a multicenter cohort study. J Alzheimers Dis. 2016 Oct 18;54(4):1649-57. Resumo

26. Janvin C, Larsen J, Salmon D, et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease. Mov Disord. 2006 Mar;21(3):337-42. Resumo

27. Tiraboschi P, Salmon D, Hansen L, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? 2006 Mar;129(Pt 3):729-35.Texto completo  Resumo

28. Burn DJ. Cortical Lewy body disease and Parkinson's disease dementia. Curr Opin Neurol. 2006 Dec;19(6):572-9. Resumo

29. Ferman TJ, Boeve BF, Smith GE, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011 Aug 30;77(9):875-82. Resumo

30. Salmon DP, Galasko D, Hansen LA, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn. 1996 Jul;31(2):148-65. Resumo

31. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. Jun 2018 [internet publication].Texto completo

32. Watson R, Blamire AM, O'Brien JT. Magnetic resonance imaging in Lewy body dementias. Dement Geriatr Cogn Disord. 2009;28(6):493-506.Texto completo  Resumo

33. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol. 2007 Feb;27(1):42-7. Resumo

34. Fischer C, Bozanovic R, Atkins JH, et al. Treatment of delusions in dementia with Lewy bodies: response to pharmacotherapy. Dement Geriatr Cogn Disord. 2007;23(5):307-11. Resumo

35. Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015 Aug 1;172(8):731-42.Texto completo  Resumo

36. Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Apr 20;74(16):1316-24.Texto completo  Resumo

37. Dickson DW. Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol. 2001 Aug;14(4):423-32. Resumo

38. McKeith IG. Dementia with Lewy bodies. Br J Psychiatry. 2002 Feb;180:144-7.Texto completo  Resumo

39. O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-68.Texto completo  Resumo

40. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504.Texto completo  Resumo

41. Crecelius C. Diagnosis and treatment of non-Alzheimer's dementias. J Am Med Dir Assoc. 2003 Jul-Aug;4(4 Suppl):H25-9. Resumo

42. Figiel G, Sadowsky C. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin. 2008 Jan;24(1):157-66. Resumo

43. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):164-71.Texto completo  Resumo

44. McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord. 2004 May;10 Suppl 1:S15-8. Resumo

45. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007 Jan;14(1):e1-26.Texto completo  Resumo

46. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009 Jul;8(7):613-8. Resumo

47. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. Resumo

48. Johansson CB, Ballard C, Hansson O, et al. Efficacy of memantine in PDD and DLB: An extension study including washout and open-label treatment. Int J Geriatr Psychiatry. 2011 Feb;26(2):206-13. Resumo

49. Collerton D, Taylor JP. Advances in the treatment of visual hallucinations in neurodegenerative diseases. Future Neurol. 2013 Jul;8(4):433-444.Texto completo  Resumo

50. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007 Jun 5;146(11):775-86. Resumo

51. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007 Feb 27;176(5):627-32.Texto completo  Resumo

52. Drach LM. Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia: common features and differences [in German]. Med Monatsschr Pharm. 2011 Feb;34(2):47-52. Resumo

53. Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):36-42.Texto completo  Resumo

54. Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord. 2005 Aug;20 Suppl 12:S77-82. Resumo

55. Kurtz AL, Kaufer DI. Dementia in Parkinson's disease. Curr Treat Options Neurol. 2011 Jun;13(3):242-54. Resumo

56. Substance Abuse and Mental Health Services Administration. Emergency department visits involving nonmedical use of the anti-anxiety medication alprazolam. The CBHSQ Report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2014.Texto completo

57. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003 Jul;4(4):281-4. Resumo

58. McGrane IR, Leung JG, St Louis EK, et al. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015 Jan;16(1):19-26.Texto completo  Resumo

59. Molloy S, McKeith IG, O'Brien JT, et al. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1200-3.Texto completo  Resumo

60. Friedman JH. Parkinson disease psychosis: update. Behav Neurol. 2013 Jan 1;27(4):469-77.Texto completo  Resumo

61. Lucetti C, Logi C, Del Dotto P, et al. Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010 Sep;16(8):522-6. Resumo

62. Orgeta V, Qazi A, Spector AE, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2014 Jan 22;(1):CD009125.Texto completo  Resumo

63. Williams MM, Xiong C, Morris JC, et al Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67:1935-1941. Resumo

64. Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013;56:1-9. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal